YIMMUGO® Now Available in the U.S.: Kedrion Biopharma Commercializes a New Ig Therapy for PI

Kedrion Biopharma is proud to announce the U.S. availability of YIMMUGO (Immune Globulin Intravenous, Human-dira, 10%), ...
Healio

FDA approves Qivigy for adults with primary humoral immunodeficiency

The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary ...
MPR

Qivigy Approved for Primary Humoral Immunodeficiency in Adults

Qivigy (immune globulin intravenous, human-kthm) is a ready-to-use, sterile, non-pyrogenic liquid solution of human immune globulin for IV administration.
The Pharma Letter

Grifols’ Biotest to launch Yimmugo in USA

Spanish plasma-based medicines producer Grifols announced that Yimmugo, an innovative intravenous immunoglobulin (IVIg) ...
The American Journal of Managed Care

Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis

Efgartigimod demonstrated superior efficacy over IVIG in improving MG-ADL and QMG scores in myasthenia gravis patients. Patients treated with efgartigimod experienced faster symptom improvement and ...